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Identity 
Other names: CSBP1; CSBP2; CSPB1; EXIP; Mxi2; 
PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA 
HGNC (Hugo): MAPK14 
Location: 6p21.31 
DNA/RNA 
Description 
The gene spans a region of 83.53 kb and the coding 
part is divided into 41 different exons.  
Larger transcripts contain 12 or 13 exons. 
(GATExplorer). 
Transcription 
9 types of transcripts have been described, although 
only 5 are protein coding transcripts. The larger 4319-
nucleotide transcript encodes a protein of 360 amino 
acid residues. The first and last exons are partially 
untranslated. 
Pseudogene 
None described so far. 
 
 
Schematic representation of human chromosome 6 indicating the position of MAPK14 locus (p21.31) (red bar). 
 
 
MAPK14 gene locus. Representation of the MAPK14 gene organization indicating the position of the exons (coding region) and 
untranslated regions. 
 
 
 
 
 
MAPK14 (mitogen-activated protein kinase 14) Porras A, Guerrero C 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2011; 15(8)  629 
 
MAPK14 protein domains. Schematic representation of MAPK14 protein indicating the position of its functional domains. 30-54: protein 
kinase ATP signature, ATP-binding region; 59-162: MAPK signature; 24-308: protein kinase domain. 
 
Protein 
Description 
MAPK14 is a Ser/Thr kinase composed of 90 to 360 
residues depending on the transcript variant. 
 
Crystal structure of MAPK14 at 2.3 A resolution. From PDB 
(access number: 1WFC). 
Expression 
p38alpha MAPK is ubiquitously expressed, being the 
p38 most abundant isoform. 
Localisation 
p38alpha is mainly present in the cytosol, but it can 
translocate to the nucleus. In addition, it can be 
localized in the mitochondria or in other subcellular 
compartments. 
Function 
p38alpha is mainly activated by various environmental 
stresses and proinflammatory cytokines, but many 
other extracellular signals, including growth factors, 
also lead to p38alpha activation. The canonical 
activation requires its phosphorylation in threonine and 
tyrosine residues by dual-specificity MAP kinase 
kinases (MKKs), MKK3, MKK6 and MKK4. 
Substrates of this kinase include transcription factors, 
such as ATF1, ATF2, ATF6, p53, MEF2 or C/EBPbeta 
and protein kinases, such as MAPKAP-K2 and 
MAPKAP-K3 (also known as MK-2 and MK-3), MSK-
1, MNK-1/MNK-2 and other proteins.  
p38alpha MAPK is essential for embryonic  
development and it regulates different cellular 
functions such as proliferation, differentiation, cell 
death, adhesion, migration, as well as the response to 
stress and many metabolic pathways, among others. It 
does so through regulation of transcription, mRNA 
stability, chromatin remodelling, protein synthesis, etc.  
Concerning cell death, although p38alpha plays an 
important role as a pro-apoptotic signal, it can play a 
dual role, acting as either a mediator of cell survival or 
of cell death, depending on the cell type and the 
stimuli. Related with its function as a negative 
regulator of proliferation and a mediator of apoptosis, 
p38alpha acts as a tumor suppressor in the initial stages 
of a tumorigenic process, while at later stages it can 
promote metastasis. 
 
Signaling through p38alphaMAPK. Signaling through 
MAPK14 cascade and its role in the regulation of cellular 
functions. MAPK14 is involved in signaling pathways triggered 
by a variety of stimuli such as growth factors, oxidative stress, 
UV, cytokines and DNA damage. Depending on the stimulus, 
different receptors and intermediates (adaptors, GTPases or 
kinases) are activated leading to the activation of the p38alpha 
MAPK cascade. This cascade is initiated by activation of 
MAPKKKs, which phosphorylate and activate MAPKKs 
(MKK3/6/4), which in turn lead to activation of MAPK14 through 
dual phosphorylation in Tyr and Thr. Once phosphorylated, 
MAPK14 phosphorylates a number of cytosolic and nuclear 
substrates, including transcription factors, which lead to the 
control of many cellular responses. 
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Mutations 
Somatic 
4 somatic mutations according to Ensembl: 
COSM21366; COSM20563; COSM35409; 
COSM12875. 
Implicated in 
Hematopoietic malignancies 
Disease 
p38 MAPK, mainly the p38alpha isoform, is a key 
player in the maintenance of hematopoiesis 
homeostasis, as it balances both proliferative and 
growth inhibitory signals triggered by the growth 
factors and cytokines that regulate normal 
hematopoiesis. Alterations in this p38 MAPK-
controlled balance may result in either overproduction 
or depletion of myelosuppressive cytokines leading to 
the development of certain bone marrow failure 
syndromes. For example, p38alpha is responsible for 
the enhanced stem cell apoptosis characteristic of low 
grade myeolodysplastic syndromes (MDSs). On the 
other hand, imbalance toward the proliferative side may 
conduct to the development of myeloproliferative 
syndromes (MPSs), such as leukemia, lymphomas and 
myelomas. In particular, p38alpha MAPK plays a pro-
apoptotic role in chronic myeloid leukemia (CML). In 
fact, p38alpha MAP kinase pathway mediates the 
growth inhibitory effects of IFNalpha and STI-571, two 
drugs used in the CML treatment, which underscores 
the importance of this pathway in the generation of 
antileukemic responses. 
Alzheimer's disease 
Disease 
Alzheimer is an incurable, neurodegenerative disease 
characterized by a progressive deterioration of the 
cognitive, memory and learning ability due to the 
accumulation of plaques containing amyloidogenic 
Abeta proteins and tangles containing 
hyperphosphorylated tau protein. The ASK1-MKK6-
p38 signaling pathway participates in amyeloid 
precursor protein (APP) and tau phosphorylation in 
response to oxidative stress and contributes to the 
expression of the beta-secretase gene and the induction 
of neuronal apoptosis triggered by ROS. 
Parkinson disease 
Disease 
Parkinson is a degenerative disorder of the central 
nervous system characterized by muscle rigidity, 
tremor and loss of physical movement caused by a 
progressive loss of dopaminergic neurons. Mutations in 
alpha-synuclein are one of the main causes of 
Parkinson. alpha-synuclein activates p38alpha MAPK 
in human microglia promoting a potent inflammatory 
stimulation of microglial cells. Additionally, the 
p38alpha MAPK plays a role in dopaminergic neural 
apoptosis through the phosphorylation of p53 and 
expression of the pro-apoptotic protein Bax. 
Amyotrophic lateral sclerosis 
Disease 
ALS is a progressive, lethal, degenerative disorder of 
motor neurons leading to paralysis of voluntary 
muscles. Numerous evidences point to a role of p38 
MAPK in the development and progression of ALS 
induced by mutations in SOD1 (superoxide dismutase 
1) gene. Mutant SOD1 provokes aberrant oxyradical 
reactions that increase the activation of p38 MAPK in 
motor neurons and glial cells. This increase in active 
p38 MAPK may phosphorylate cytoskeletal proteins 
and activate cytokines and nitric oxide, thus 
contributing to neurodegeneration through different 
mechanisms including apoptosis. 
To be noted 
Note 
See also the Deep Insight: "Role of p38alpha in 
apoptosis: implication in cancer development and 
therapy". 
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